CRESCENDO: EFC5826: Randomized, Multinational, Multicenter, Double-Blind, Placebo-Controlled, Two-Arm Parallel Group Trail of Rimonabant 20 mg QD for Reducing the Risk of Major Cardiovascular Events in Abdominally Obese Patients with Clustering

  • Ziada, Khaled (PI)
  • Steinhubl, Steven (Former PI)

Grants and Contracts Details

StatusFinished
Effective start/end date11/1/06 → 6/30/10